Biotech Values

[rfj1862]

I would say that it will be hard for ARQT to make serious money in topical derm. I can’t think of a topical derm product that became more than a modest seller.

I was just looking at comparables and Opzelura sold $61 million in Q4 for short-term atopic dermatitis and vitiligo; so say $240 million a year for 2 indications.

It looks like topical roflumilast is indicated for plaque psoriasis, will definitely be indicated for atopic dermatitis based on trial results, and is almost certainly going to gain indications for seborrheic dermatitis and (as a foam) scalp psoriasis. It is extremely well tolerated relative to other options out there.

This is setting aside the topical JAK and the biologic in preclinical.